Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy
Introduction
Neutron-capture therapy (NCT) applied to malignant tumors utilizes the nuclear neutron capture reaction of radiation-producing agents. Coupled with several elements, it was first postulated by Locher (1936). The most common element for NCT is boron (B-NCT), and the clinical outcome with the use of B-NCT has been good in patients with malignant melanoma (Mishima et al., 1989). Nonetheless, other more effective radiation-producing elements for NCT are still required. Gadolinium is also a radiation-producing element that provides the neutron capture reaction by thermal neutron irradiation. NCT with gadolinium (Gd-NCT) has several advantages over B-NCT, in that not only does gadolinium have a higher thermal neutron capture cross-section (66 times larger than that of boron) (Garber and Kinsey, 1976), but it is also used as a diagnostic agent in enhanced magnetic resonance imaging (MRI) examinations and shows promise in future Gd-NCT therapy under enhanced MRI diagnosis (Fig. 1). Although the therapeutic potential of Gd-NCT has been explored in recent years, there is no study on therapy applied to musculoskeletal tumors such as sarcoma. The future success of clinical Gd-NCT trials will depend on both the visualization of tumor cells on enhanced MRI and the selectively large accumulation of gadolinium compounds in individual tumor cells. Consequently, we used a sarcoma cell line, malignant fibrosis histiocytoma (MFH) Nara-H, in this study to determine whether the accumulation of gadolinium in the cells could be detected by the MRI system. Both the commercially available MRI contrast agent Gd-DTPA (Magnevist®, dimeglumine gadopentetate aqueous solution) and the biodegradable and highly gadopentetic acid (Gd-DTPA)-loaded chitosan nanoparticles (Gd-nanoCPs) prepared by a novel emulsion-droplet coalescence technique were used (Tokumitsu et al., 1999).
Section snippets
Materials and methods
The Human sarcoma cell line, (MFH) Nara-H, was cultured in Eagle's minimum essential medium (MEM) supplemented with antibiotic–antimycotic solution and fetal bovine serum (FBS), and incubated in a humidified atmosphere of 5% CO2 in air at 37 °C. An adequate number of cells produced in the initial culture were harvested, re-seeded in three 75 cm2 cell-culture flasks at a density of 1000 cells/flask and cultured for 10 days. When the culture reached 70% confluence, the culture medium was aspirated.
Phantom model: making and visualizing the cell pellets as a tumor mass under the MRI system
Although almost 5 mm in diameter, the pellets responded well to the MRI examination. The phantom model was very easy to set, and the gadolinium signal intensity from the phantom tumor mass was successfully acquired under the commercially used MRI system (Fig. 3, Fig. 4). Although the pellets were very small, MR signal intensity was detected clearly and measured to the center of the pellets. No other studies have shown MR signals from malignant cell line mass. This phantom model also suggests
Conclusions
The accumulation of both commercially available MRI contrast agent Gd-DTPA (Magnevist®, dimeglumine gadopentetate aqueous solution) and Gd-nanoCPs was detected by MRI. Although Gd-nanoCPs demonstrated a smaller reduction of T1, their accumulation of gadolinium was larger than that of Gd-DTPA.
Acknowledgments
This work was supported by in part by Grant-in-Aid for Scientific Research 18659446 and Core-to-Core Program for “Advanced Particle Handling Technology” from Japan Society for the Promotion of Science, “Academic Frontier” Project 2006-2010 for Private Universities from Japanese Ministry of Education, Culture, Sports, Science and Technology, and Grant-in-Aid from Association for Nuclear Technology in Medicine.
References (13)
In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer
Eur. J. Pharm. Biopharm.
(2002)Gadolinium neutron-capture therapy using novel gadopentetic acid–chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor
Cancer Lett.
(2000)Suppression of rabbit VX-2 subcutaneous tumor growth by gadolinium neutron capture therapy
Jpn. J. Cancer Res.
(1993)Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours
Lancet
(1984)Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy
Cancer Res.
(2001)- et al.
Pseudolayering of Gd-DTPA in the urinary bladder
Radiology
(1990)